Navigation Links
Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug
Date:6/22/2009

n in the male reproductive tract and is a mandatory co-factor of fertilization in the female reproductive tract. Cordex's sponsored studies have shown that ATP treatment can improve the motility and fertilization capacity of malfunctioning sperm obtained from infertile males due to asthenozoospermia as well as thawed sperm that had been cryopreserved.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. ATPace(TM) is expected to enter a Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Cordex's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary diseases. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations,
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
6. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
7. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
8. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
11. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... quarter and fiscal year ended June 30, 2014 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that ... Eastern Time on Monday, December 20, to discuss results of ... retinal vein occlusion (CRVO) and the week 52 follow-up results ... diabetic macular edema (DME).  A press release will be issued ...
... Institute, the Department of Orthopaedic Surgery and the Division ... of Pennsylvania (HUP) have collaborated to form the Penn ... leadership of the Penn Transplant Institute and in collaboration ... organ and tissue donor program which serves the eastern ...
Cached Medicine Technology:Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2Penn Medicine Establishes Hand Transplant Program 2Penn Medicine Establishes Hand Transplant Program 3Penn Medicine Establishes Hand Transplant Program 4Penn Medicine Establishes Hand Transplant Program 5
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... the Obama Daughters , , WASHINGTON, ... promise: to get a family dog. But concerns about his ... first-dad from making a decision. So, in the meantime, the ... & allergy friendly" toy puppies to the Obama children. , ...
... with imaging exam results may enable a more meticulous ... as a more personal and empathetic approach, according to ... the Radiological Society of North America (RSNA). , ... being and not as an anonymous case study," said ...
... December 2, 2008 As the connection between second-hand ... legislation was passed to reduce such passive smoking, exposures ... January 2009 issue of the American Journal of ... San Francisco, Partners Healthcare, Boston and Columbia University have ...
... POCATELLO, Idaho, Dec. 1 The Ensign Group, Inc.,(Nasdaq: ... & Rehabilitation Center in,Pocatello, Idaho has successfully graduated from ... , (Logo: ... A clinical team led by Laurie House, Director ...
... In the face of one of the most,severe economic ... Board of,Directors has approved an investment of up to ... Plan. Employee pension plans, which are,often heavily invested in ... the nation,s worsening economy. Although conservatively,invested, the Sutter Health ...
... - Disturbing evidence of higher mortality and lower surgery ... and severe leakage may be related to the complexity ... findings of a Mayo Clinic study published this month ... Mitral valve prolapse affects approximately 150 million people worldwide ...
Cached Medicine News:Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:Patient photos spur radiologist empathy and eye for detail 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: